Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (26672)	11/25/1998 11:31:00 AM
From: Machaon	Read Replies (2) \| Respond to of 32384

Latest Lehman LGND recommendation at: lehman.com They are forecasting .78 earnings for 2000, keeping with a 1-buy rec, and have a 12 month price target of $24 (unchanged) I found it interesting that the AIDS patient on the panel, who was the only one who voted against approval, said that a reason that he voted against Panretin Gel for KS was because he felt that there would be limited demand for the product, since there were very few new cases of KS. Lehman estimates currently about 20,000 patients in a decreasing market. They estimate peak annual sales, for Panretin, of about $26 million. In order to read the Lehman article about LGND you may need to download the latest copy of Acrobat Reader at: adobe.com Regards, Bob